Therapeutic approaches using genetically modified cells

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
Brigitte AnlikerMatthias Schweizer

Abstract

Medicinal products containing genetically modified cells are, in most cases, classified as gene therapy and cell therapy medicinal products. Although no medicinal product containing genetically modified cells has been licensed in Europe yet, a variety of therapeutic strategies using genetically modified cells are in different stages of clinical development for the treatment of acquired and inherited diseases. In this chapter, several examples of promising approaches are presented, with an emphasis on gene therapy for inherited immunodeficiencies and on tumour immunotherapy with genetically modified T-cells expressing a chimeric antigen receptor or a recombinant T-cell receptor.

References

Apr 27, 2005·Nature Medicine·Mark H TuszynskiJames Conner
Nov 30, 2007·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·C BaumA Thrasher
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emily K MaderKah-Whye Peng
Sep 14, 2010·Expert Opinion on Biological Therapy·Ignacio García-GómezDamián García-Olmo
Jan 7, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Xiaoyang LingMichael Andreeff
Jan 21, 2011·Cancer Metastasis Reviews·Trina J Stewart, Mark J Smyth
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Mar 8, 2012·Journal of the National Cancer Institute·Jeffrey Schlom
Jul 14, 2012·Blood·Amel HassanUNKNOWN Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation and European Society for Immunodefici
Dec 6, 2012·Experimental Hematology & Oncology·Kemeng WangDelong Liu
May 15, 2013·Trends in Biotechnology·Thomas GajCarlos F Barbas
May 31, 2013·Gene Therapy·L ZhangH B Gaspar
Nov 8, 2013·Current Gene Therapy·Michael RotheAxel Schambach
Jan 16, 2014·Annual Review of Immunology·Marcela V MausCarl H June
Jan 17, 2014·Cancer Immunology Research·Marcela V MausCarl H June
Jan 28, 2014·International Journal of Molecular Sciences·Robert D WyseJulien Rossignol
Mar 14, 2014·Science Translational Medicine·Christian Jörg BraunChristoph Klein
Mar 29, 2014·The Cancer Journal·Shannon L MaudeStephan A Grupp
Apr 30, 2014·Cancer Immunology Research·Marcela V MausCarl H June
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Oct 30, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jordi Martinez-QuintanillaKhalid Shah
Dec 17, 2014·Immunological Reviews·Saar Gill, Carl H June
Mar 17, 2015·Methods : a Companion to Methods in Enzymology·Ji Sun ParkKam W Leong
Apr 11, 2015·Human Gene Therapy·Maria Pia Cicalese, Alessandro Aiuti

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Molecular and Cell Biology of Human Diseases Series
C Kinnon
Springer Seminars in Immunopathology
F Candotti, R M Blaese
Advances in Nephrology From the Necker Hospital
A FischerM Cavazzana-Calvo
© 2021 Meta ULC. All rights reserved